In order to examine the possible role of WT1 gene overexpression in assessing treatment response, prognosis and survival of AML patients with normal cytogenetics, All CN-AML patients were divided into three different risk subgroups based on their known molecular abnormalities such as the FLT3 and NPM1 gene mutation statuses. The gene discussed is WT1; the disease is acute myeloid leukemia.